MedTrace Logo

The Effect of Vasopressors on Cerebral Oxygentaion During Off Pump CABG

NCT04214145 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-05-09

No results posted yet for this study

Summary

The purpose of this study is to analyze the changes in cerebral oxygen saturation during the use of three vasopressors, phenylephrine, norepinephrine, and vasopressin, which are currently used during coronary artery bypass grafting.

Conditions

  • Cerebral Oxygen Saturation

Interventions

DRUG

Phenylephrine

Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg. 1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr) 2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes 3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)

DRUG

Norepinephrine

Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg. 1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr) 2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes 3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)

DRUG

Vasopressin

Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg. 1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr) 2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes 3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-07
Primary Completion
2021-09-02
Completion
2021-09-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04214145 on ClinicalTrials.gov